MX9306006A - ANTAGONIST COMBINATIONS IBUPROFEN-H2. - Google Patents
ANTAGONIST COMBINATIONS IBUPROFEN-H2.Info
- Publication number
- MX9306006A MX9306006A MX9306006A MX9306006A MX9306006A MX 9306006 A MX9306006 A MX 9306006A MX 9306006 A MX9306006 A MX 9306006A MX 9306006 A MX9306006 A MX 9306006A MX 9306006 A MX9306006 A MX 9306006A
- Authority
- MX
- Mexico
- Prior art keywords
- ibuprofen
- heartburn
- lysine
- relief
- salt
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 201000006549 dyspepsia Diseases 0.000 abstract 4
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 208000024798 heartburn Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 210000002784 stomach Anatomy 0.000 abstract 2
- IHHXIUAEPKVVII-PYTFSAHDSA-N (2r)-2,6-diaminohexanoic acid;(2s)-2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound NCCCC[C@@H](N)C(O)=O.CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 IHHXIUAEPKVVII-PYTFSAHDSA-N 0.000 abstract 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- IHHXIUAEPKVVII-PTKYJSHISA-N [(5s)-5-amino-5-carboxypentyl]azanium;(2s)-2-[4-(2-methylpropyl)phenyl]propanoate Chemical group NCCCC[C@H](N)C(O)=O.CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 IHHXIUAEPKVVII-PTKYJSHISA-N 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 abstract 1
- 229960001680 ibuprofen Drugs 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020830 overeating Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención se refiere a composiciones farmacéuticas para usarse en eltratamiento del dolor e inflamación y en el alivio de la indigestión,estómago ácido, ardor del corazón y otros desordenes gastro intestinalesen los mamíferos incluyendo los seres humanos al administrar composicionesque comprendan (i) una cantidad efectiva analgélsicamente y antiinflamatoriamente de una sal de ibuprofeno (s) básicamente libre deibuprofeno(R) en donde la sal se selecciona desde (s)ibuprofeno-(s)-lisina y (s)-ibuprofeno-(R)-lisina; y (ii) una cantidadefectiva en el alivio de la indigestión estómago ácido, ardor de corazón,exceso de comer, y otros desordenes gastro intestinales de por lo menosuno de los antagonistas H2.This invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation and in the relief of indigestion, acid stomach, heartburn, and other gastrointestinal disorders in mammals including humans when administering compositions comprising (i) an effective amount. analgesically and anti-inflammatory of a salt of ibuprofen (s) basically free of ibuprofen (R) where the salt is selected from (s) ibuprofen- (s) -lysine and (s) -ibuprofen- (R) -lysine; and (ii) a deficient amount in the relief of acid stomach indigestion, heartburn, overeating, and other gastro-intestinal disorders of at least one of the H2 antagonists.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95344092A | 1992-09-29 | 1992-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9306006A true MX9306006A (en) | 1995-01-31 |
Family
ID=25493996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9306006A MX9306006A (en) | 1992-09-29 | 1993-09-28 | ANTAGONIST COMBINATIONS IBUPROFEN-H2. |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0663839A4 (en) |
| JP (1) | JPH08502254A (en) |
| AU (1) | AU4931693A (en) |
| CA (1) | CA2144155A1 (en) |
| MX (1) | MX9306006A (en) |
| WO (1) | WO1994007541A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2349575A1 (en) | 1998-11-17 | 2000-05-25 | Nitromed, Inc. | Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
| SE0000774D0 (en) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| EP2260837A1 (en) | 2001-06-01 | 2010-12-15 | Pozen, Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| SE0102993D0 (en) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| US8067451B2 (en) | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
| US20070043097A1 (en) * | 2005-07-18 | 2007-02-22 | Horizon Therapeutics, Inc. | Medicaments containing famotidine and ibuprofen and administration of same |
| US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
| US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
| ATE539747T1 (en) * | 2006-07-18 | 2012-01-15 | Horizon Therapeutics Inc | METHOD AND MEDICATION FOR ADMINISTRATION OF IBUPROFEN |
| CA2930063C (en) | 2008-01-04 | 2017-01-31 | Schabar Research Associates Llc | Unit oral solid dose compositions composed of naproxen sodium and nizatidine |
| MX2011002515A (en) | 2008-09-09 | 2011-04-07 | Astrazeneca Ab | Method for delivering a pharmaceutical composition to patient in need thereof. |
| SG176724A1 (en) | 2009-06-25 | 2012-01-30 | Astrazeneca Ab | Method for treating a patient at risk for developing an nsaid-associated ulcer |
| EP2797600A4 (en) | 2011-12-28 | 2015-09-16 | Pozen Inc | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| WO2015163832A1 (en) * | 2014-04-25 | 2015-10-29 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | An ibuprofen and famotidine combined composition having improved stability |
| IL299845A (en) | 2020-07-15 | 2023-03-01 | Schabar Res Associates Llc | Oral unit dose compounds consisting of ibuprofen and famotidine for the treatment of acute pain and to reduce the severity and/or risk of heartburn |
| CA3124579A1 (en) | 2020-07-15 | 2022-01-15 | Schabar Research Associates Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY1398A (en) * | 1981-09-04 | 1987-12-18 | Glaxo Group Ltd | Pharmaceutical compositions containing non-steroidal anti-inflammatory agents |
| NZ235877A (en) * | 1989-11-02 | 1992-09-25 | Mcneil Ppc Inc | Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence |
| US4994604A (en) * | 1990-01-10 | 1991-02-19 | Merck & Co., Inc. | Formation and resolution of ibuprofen lysinate |
| US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
-
1993
- 1993-09-21 CA CA002144155A patent/CA2144155A1/en not_active Abandoned
- 1993-09-21 AU AU49316/93A patent/AU4931693A/en not_active Abandoned
- 1993-09-21 EP EP93921709A patent/EP0663839A4/en not_active Withdrawn
- 1993-09-21 WO PCT/US1993/008947 patent/WO1994007541A1/en not_active Application Discontinuation
- 1993-09-21 JP JP6509138A patent/JPH08502254A/en active Pending
- 1993-09-28 MX MX9306006A patent/MX9306006A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0663839A1 (en) | 1995-07-26 |
| EP0663839A4 (en) | 1998-06-03 |
| CA2144155A1 (en) | 1994-04-14 |
| AU4931693A (en) | 1994-04-26 |
| JPH08502254A (en) | 1996-03-12 |
| WO1994007541A1 (en) | 1994-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9306006A (en) | ANTAGONIST COMBINATIONS IBUPROFEN-H2. | |
| US4704405A (en) | Rapid acting combination of sodium sulindac and a base | |
| Ferrer-Brechner et al. | Combination therapy with ibuprofen and methadone for chronic cancer pain | |
| US6689399B1 (en) | Transdermal delivery of an anti-inflammatory composition | |
| EP0174006A3 (en) | Antidiarrheal compositions and use thereof | |
| NZ235877A (en) | Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence | |
| JPS61197517A (en) | Drug composition | |
| JPH04230330A (en) | Combination drug and method for relieving gastroenteric symptom arising from nonsteroidal anti inflammatory drug | |
| MX9304564A (en) | COMBINATIONS OF MUSCLE RELAXANT-IBUPROFEN. | |
| FR2385398A1 (en) | ANTI-INFLAMMATORY COMPOSITIONS CONTAINING A PHOSPHONATE-TYPE COMPOUND AND A SALICYLATE-TYPE COMPOUND | |
| AU656140B2 (en) | Pharmaceutical compositions and methods for alleviating gastrointestinal distress symptoms induced by nonsteroidal anti-inflammatory drugs | |
| MX9304563A (en) | DEXIBUPROFEN / ANTI-ACID / SIMETICONE COMBINATIONS | |
| DE3366910D1 (en) | Pharmaceutical compositions and preparation thereof | |
| Mardirossian et al. | Comparison of the analgesic efficacy of flurbiprofen and aspirin for postsurgical dental pain | |
| JPH0314812B2 (en) | ||
| Stalnikowicz et al. | Cimetidine decreases indomethacin induced duodenal mucosal damage in patients with acute musculoskeletal disorders. | |
| EP0017169B1 (en) | Improved anti-inflammatory combinations having reduced ulcerogenicity | |
| US20060141027A1 (en) | Sublingual administration of non-steroidal anti-inflammatory pharmacological substances | |
| WHEATLEY | Analgesic properties of fluproquazone | |
| IL70407A (en) | Synergistic analgesic pharmaceutical compositions in unit dosage form,comprising an analgesic agent and hydroxyzine | |
| Rodrigo et al. | Sucralfate and cimetidine as maintenance treatment in the prevention of duodenal ulcer recurrence | |
| Kajanoja | Indomethacin in the treatment of primary dysmenorrhoea | |
| Paladini et al. | Prophylactic and therapeutic role of rioprostil in NSAIDs induced gastroduodenal lesions | |
| Bakshi et al. | Efficacy and tolerability of diclofenac dispersible in painful osteoarthrosis | |
| Babb | Cimetidine: clinical uses and possible side effects |